Advos

Wearable Devices Ltd. will exhibit its AI-powered neural sensing technology for Physical AI and humanoid robotics at the Physical AI 2026 event, highlighting its role in advancing human-machine interaction.

Faraday Future Intelligent Electric Inc. will present its latest robotics initiatives at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference, highlighting its strategic shift toward Embodied AI and Physical AI ecosystem.

As geopolitical turmoil disrupts global oil supplies, Frontieras North America Inc. is advancing a project to convert abundant American coal into essential fuels and materials domestically, aiming to reduce U.S. reliance on imported crude.

Cyabra Inc. was featured at Moody Capital Solutions' Disruptive Growth & Life Sciences Conference, highlighting its AI-driven platform that detects manipulated content and inauthentic actors to protect organizations and brands online.

Elon Musk and Mark Zuckerberg called on G20 countries to support rapid data center expansion for AI, a move that could shape global tech policy and impact AI companies.

Quantum BioPharma's FDA clearance to test Lucid-MS in phase 2 trials marks a potential breakthrough in multiple sclerosis treatment by targeting myelin repair, a first for this mechanism.

OS Animal Health, a subsidiary of OS Therapies, showcased its innovative HER2-targeting immunotherapy for canine osteosarcoma at the Moody Capital Solutions 2026 Disruptive Growth and Life Sciences Conference, highlighting its potential to transform veterinary oncology.

A new study from Washington University School of Medicine highlights the growing role of laser interstitial thermal therapy (LITT) in brain cancer treatment, offering a less invasive alternative to open surgery and potentially improving patient outcomes.

Impala Platinum's enhanced dividends highlight a market recovery for platinum group metals, prompting analysts to watch how other producers allocate profits.

Ocumetics Technology Corp. has initiated patient recruitment for its Group Two human clinical study, marking a critical step in evaluating the safety and vision performance of its next-generation accommodating intraocular lens.

Quantum BioPharma's Lucid-MS, a first-in-class drug candidate for multiple sclerosis, has received FDA clearance for Phase 2 trials, potentially marking the first time a therapy of this mechanism is tested in patients, offering hope for disease modification and repair.

NanoViricides has registered its Phase II clinical trial for NV-387 Oral Gummies as a treatment for Ebola in the Democratic Republic of Congo, marking a significant step in developing an oral antiviral against Ebola.

Datavault AI Inc. announced the upcoming launch of its three data exchange platforms, marking its shift from development to commercial deployment and aiming to monetize data assets across various sectors.

LaFleur Minerals is progressing from recommissioning to gold production at its fully permitted Beacon Gold Mill, positioning it as a near-term producer in Canada's Abitibi Gold Belt.

Nutriband Inc. received a USPTO Notice of Publication for trademarks related to its abuse-deterrent fentanyl patch, moving closer to commercial launch and addressing the opioid crisis.

Greenland Mines announced its Q4 2026 biotech spin-off and other milestones as it transitions to a pure-play critical minerals company, with a positive economic assessment for its Sarfartoq project.

tZERO's correspondent clearing relationship with Archax Markets will provide regulated custody, clearing, and trading infrastructure for the broker-dealer's planned U.S. offering of tokenized securities.

Quantum BioPharma has received FDA clearance to begin a Phase 2 trial of its investigational multiple sclerosis drug Lucid-MS, a first-in-class candidate that targets demyelination rather than broadly suppressing the immune system.

Quantum BioPharma's Lucid-MS has received FDA clearance for a Phase 2 trial in MS, marking a step toward a targeted treatment for demyelination.

Quantum BioPharma received FDA clearance to begin a Phase 2 trial for Lucid-MS, a novel multiple sclerosis treatment, marking a significant step toward a new therapy that targets demyelination rather than suppressing the immune system.